BACKGROUND: Many countries have acquired antiviral stockpiles for pandemic influenza mitigation and a significant part of the stockpile may be focussed towards community-based treatment. METHODS: We developed a spreadsheet-based, decision tree model to assess outcomes averted and cost-effectiveness of antiviral treatment for outpatient use from the perspective of the healthcare payer in the UK. We defined five pandemic scenarios-one based on the 2009 A(H1N1) pandemic and four hypothetical scenarios varying in measures of transmissibility and severity. RESULTS: Community-based antiviral treatment was estimated to avert 14-23% of hospitalizations in an overall population of 62.28 million. Higher proportions of averted outcomes were seen in patients with high-risk conditions, when compared to non-high-risk patients. We found that antiviral treatment was cost-saving across pandemic scenarios for high-risk population groups, and cost-saving for the overall population in higher severity influenza pandemics. Antiviral effectiveness had the greatest influence on both the number of hospitalizations averted and on cost-effectiveness. CONCLUSIONS: This analysis shows that across pandemic scenarios, antiviral treatment can be cost-saving for population groups at high risk of influenza-related complications. Published by Oxford University Press on behalf of Faculty of Public Health [2018]. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: Many countries have acquired antiviral stockpiles for pandemic influenza mitigation and a significant part of the stockpile may be focussed towards community-based treatment. METHODS: We developed a spreadsheet-based, decision tree model to assess outcomes averted and cost-effectiveness of antiviral treatment for outpatient use from the perspective of the healthcare payer in the UK. We defined five pandemic scenarios-one based on the 2009 A(H1N1) pandemic and four hypothetical scenarios varying in measures of transmissibility and severity. RESULTS: Community-based antiviral treatment was estimated to avert 14-23% of hospitalizations in an overall population of 62.28 million. Higher proportions of averted outcomes were seen in patients with high-risk conditions, when compared to non-high-risk patients. We found that antiviral treatment was cost-saving across pandemic scenarios for high-risk population groups, and cost-saving for the overall population in higher severity influenza pandemics. Antiviral effectiveness had the greatest influence on both the number of hospitalizations averted and on cost-effectiveness. CONCLUSIONS: This analysis shows that across pandemic scenarios, antiviral treatment can be cost-saving for population groups at high risk of influenza-related complications. Published by Oxford University Press on behalf of Faculty of Public Health [2018]. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Luis R Carrasco; Vernon J Lee; Mark I Chen; David B Matchar; James P Thompson; Alex R Cook Journal: J R Soc Interface Date: 2011-02-04 Impact factor: 4.118
Authors: A S Monto; D M Fleming; D Henry; R de Groot; M Makela; T Klein; M Elliott; O N Keene; C Y Man Journal: J Infect Dis Date: 1999-08 Impact factor: 5.226
Authors: J A Hedrick; A Barzilai; U Behre; F W Henderson; J Hammond; L Reilly; O Keene Journal: Pediatr Infect Dis J Date: 2000-05 Impact factor: 2.129
Authors: Tom Jefferson; Mark A Jones; Peter Doshi; Chris B Del Mar; Carl J Heneghan; Rokuro Hama; Matthew J Thompson Journal: Cochrane Database Syst Rev Date: 2012-01-18
Authors: Puja R Myles; Malcolm G Semple; Wei Shen Lim; Peter J M Openshaw; Elaine M Gadd; Robert C Read; Bruce L Taylor; Stephen J Brett; James McMenamin; Joanne E Enstone; Colin Armstrong; Barbara Bannister; Karl G Nicholson; Jonathan S Nguyen-Van-Tam Journal: Thorax Date: 2012-03-10 Impact factor: 9.139
Authors: Sudhir Venkatesan; Puja R Myles; Jo Leonardi-Bee; Stella G Muthuri; Malak Al Masri; Nick Andrews; Carlos Bantar; Gal Dubnov-Raz; Patrick Gérardin; Evelyn S C Koay; Tze Ping Loh; Ziad Memish; Elizabeth Miller; Maria E Oliva; Barbara A Rath; Brunhilde Schweiger; Julian W Tang; Dat Tran; Tjasa Vidmar; Pauline A Waight; Jonathan S Nguyen-Van-Tam Journal: Clin Infect Dis Date: 2017-05-15 Impact factor: 9.079